M. Sakamoto, J. Nakajima, T. Murakawa, T. Fukami, Y. Yoshida, T. Murayama, S. Takamoto, H. Matsushita and K. Kakimi, “Adoptive Immunotherapy for Advanced Non-Small Lung Cancer Using Zoledronate-Expanded γδΤ Cells: A Phase 1 Clinical Study,” The Journal of Immunology, Vol. 34, No. 2, 2011, pp. 202-211.

has been cited by the following article:

• TITLE: Is the CD4/CD8 Ratio an Effective Indicator for Clinical Estimation of Adoptive Immunotherapy for Cancer Treatment?

  AUTHORS: Goki Shindo, Takayoshi Endo, Masamitsu Onda, Shigenori Goto, Yoju Miyamoto, Toru Kaneko

  KEYWORDS: Immunotherapy; Adoptive Activated T Lymphocyte therapy; Flow Cytometry; Performance Status; Advanced Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.8, October 29, 2013

  ABSTRACT: Background: The importance of immunotherapy in cancer treatment has been increased owing to its non-toxicity and application to personalized medicine. However, precise estimation indices of immunotherapy have yet to be established. To determine effective evaluation indices of immunotherapy for cancer treatment, we analyzed the CD4/CD8 ratio under various conditions in clinical patients with advanced cancer. Patients and Methods: Thirty-four patients who underwent one course of adoptive activated immunotherapy with or without additional conventional chemotherapy were enrolled. Before and after one course of immunotherapy, changes in the CD4/CD8 ratio were estimated by flow cytometry. Results: All patients showed a tendency toward a decrease in the CD4/CD8 ratio during a 3-month period after one course of adoptive activated T lymphocyte immunotherapy. Patients who had undergone prior surgery showed a remarkable increase in CD8 T cell number. Thus, adoptive activated T lymphocyte immunotherapy improves immunological ability against cancer invasion. The Eastern Cooperative Oncology Group’s performance status during one course of immunotherapy was significantly improved in the antecedent surgery group, with no evidence of improved PS in the non-antecedent surgery group. Patients with an increased CD4/CD8 ratio (n = 6) may have a worse outcome during adoptive activated T lymphocyte immunotherapy even with an additional course of immunotherapy. Improved actuarial survival rate of patients in the antecedent surgery group showed significant long-term benefit compared to those in the non-antecedent surgery group (p = 0.0298), as previously reported. Conclusion: The CD4/CD8 ratio is a significant indicator of outcome of adoptive activated T lymphocyte immunotherapy.